Interferon-gamma release assays (IGRAs) are a new diagnostic method for Mycobacterium TB infection.However,diagnostic value of IGRAs for extrapulmonary TB (EPTB) has not been clarified.We searched severaldatabases and selected papers with strict included criteria,evaluated the evidence of commercially available IGRAs( QuantiFERON?--TB Gold QFT-G or QFT-GIT and T-SPOT?T.TB) on blood and TST using random effectsmodels.20 studies with 1711 patients were included.After excluding the indeterminate results,the pooled sensitivity for the diagnosis of EPTB was 72％ (95％ CI,65-79％) for QFT-G or GIT and 90％ (95％CI,86-93％)for T-SPOT,the sensitivity of QFT-G or GIT in high-income countries (79％,95％CI 72-86％) was much higher than that( 29％,95％CI,14-48％) in low/middle-income countries.The pooled specificity for EPTB was 82％ (95％CI,78-87％) for QFT-G or GIT and 68％ (95％CI,64-73％) for T-SPOT.The pooled sensitivity of TST from 4studies in high-income countries was lower than that of IGRAs.T-SPOT is more sensitive to detect EPTB than QFT-G or GIT and TST.However,both IGRAs and TST have similar specificity for EPTB.IGRAs have limited value to screen and rule out EPTB as diagnostic tool,especially in low/middle-income countries.Immunosuppressive condition of patients can not affect diagnostic accuracy of IGRAs for EPTB.